12/07/2019 17:13:42

Investor Rights Alert: Halper Sadeh LLP Continues Investigating Whether the Sale of These Companies is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – AVP, TSS, EE, BKS

NEW YORK, July 12, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating Avon Products, Inc. (NYSE: AVP), Total System Services, Inc. (NYSE: TSS), El Paso Electric Company (NYSE: EE), and Barnes & Noble, Inc. (NYSE: BKS) in connection with the sale of these respective companies. On behalf of shareholders of these companies, Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Avon Products, Inc. (NYSE: AVP) 

The investigation concerns whether Avon and its Board of Directors breached their fiduciary duties and/or violated the federal securities laws in connection with the proposed sale of Avon to Natura &Co. To learn more about the Avon investigation and your legal rights and options, please visit: https://halpersadeh.com/actions/avon-products-inc-avp-natura-merger-stock/.

Total System Services, Inc. (NYSE: TSS)

The investigation concerns whether Total and its Board of Directors breached their fiduciary duties and/or violated the federal securities laws in connection with the proposed sale of Total to Global Payments Inc. for 0.8101 Global Payments shares for each share of Total common stock. To learn more about the Total merger investigation and your legal rights and options, please visit: https://halpersadeh.com/actions/total-system-services-inc-tss-merger-global-stock/.

El Paso Electric Company (NYSE: EE)

The investigation concerns whether El Paso and its Board of Directors breached their fiduciary duties and/or violated the federal securities laws in connection with the proposed sale of El Paso to the Infrastructure Investments Fund for $68.25 per share. To learn more about the El Paso merger investigation and your legal rights and options, please visit: https://halpersadeh.com/actions/el-paso-electric-company-ee-merger-jp-morgan-stock/.

Barnes & Noble, Inc. (NYSE: BKS)

The investigation concerns whether Barnes & Noble and its Board of Directors breached their fiduciary duties and/or violated the federal securities laws in connection with the proposed sale of Barnes & Noble to funds advised by Elliott Advisors (UK) Limited. To learn more about the Barnes & Noble merger investigation and your legal rights and options, please visit: https://halpersadeh.com/actions/barnes-noble-inc-merger-elliott-advisors-stock.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLP

Daniel Sadeh, Esq.

Zachary Halper, Esq.

(212) 763-0060

sadeh@halpersadeh.com

zhalper@halpersadeh.com

https://www.halpersadeh.com

hsllp_logo.jpg

Related content
16 Aug - 
SHAREHOLDER ALERT: WeissLaw LLP Reminds CHSP, EE, and T..
15 Aug - 
Shareholder Investigation Alert: Halper Sadeh LLP is In..
15 Aug - 
DFRG, EE Shareholder Class Actions: Halper Sadeh LLP An..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
2
MYGN Loss Alert: Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations
3
Bone Therapeutics SA to report half year 2019 results on 30 August 2019
4
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
5
Ambu A/S: Interim report for Q3 2018/19

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 August 2019 11:08:43
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB2 - 2019-08-22 12:08:43 - 2019-08-22 11:08:43 - 1000 - Website: OKAY